Worry about ovarian cancer risk and use of screening by high-risk women: How you recruit affects what you find

2004 ◽  
Vol 129A (2) ◽  
pp. 130-135 ◽  
Author(s):  
M. Robyn Andersen ◽  
Judy Nelson ◽  
Sue Peacock ◽  
Antoinette Giedzinska ◽  
Charles Dresher ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Cancer Risk ◽  
Ovarian Cancer Risk ◽  
High Risk Women

scholarly journals Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families

2012 ◽  
Vol 7 ◽  
pp. BMI.S10815 ◽  
Author(s):  
Ludmila Kaplun ◽  
Aviva Levine Fridman ◽  
Wei Chen ◽  
Nancy K. Levin ◽  
Sidra Ahsan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Cancer Risk ◽  
Allelic Variation ◽  
High Risk Population ◽  
Ovarian Cancer Risk ◽  
Familial Ovarian Cancer ◽  
Cell Growth And Differentiation ◽  
Brca1 Brca2 ◽  
High Risk Families

A substantial fraction of familial ovarian cancer cases cannot be attributed to specific genetic factors. The discovery of additional susceptibility genes will permit a more accurate assessment of hereditary cancer risk and allow for monitoring of predisposed women in order to intervene at the earliest possible stage. We focused on a population with elevated familial breast and ovarian cancer risk. In this study, we identified a SNP rs926103 whose minor allele is associated with predisposition to ovarian but not breast cancer in a Caucasian high-risk population without BRCA1/ BRCA2 mutations. We have found that the allelic variation of rs926103, which alters amino acid 52 of the encoded protein SH2D2A/TSAd, results in differences in the activity of this protein involved in multiple signal transduction pathways, including regulation of immune response, tumor vascularization, cell growth, and differentiation. Our observation provides a novel candidate genetic biomarker of elevated ovarian cancer risk in members of high-risk families without BRCA1/2 mutations, as well as a potential therapeutic target, TSAd.

scholarly journals A program to increase use of chemoprevention for women with high-risk breast lesions.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 46-46 ◽  
Author(s):  
Constance A. Roche ◽  
Kevin S. Hughes
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Risk ◽  
Ovarian Cancer Risk ◽  
Breast Clinic ◽  
High Risk Women ◽  
Ductal Hyperplasia ◽  
High Risk Breast ◽  
Prevention Clinic

46 Background: Tamoxifen, raloxifene, and exemestane have been demonstrated to reduce risk of breast cancer in high-risk women, bututilization is very low.Among the reasons cited are lack of awareness and reluctance of physicians to prescribe. Women with high-risk breast lesions are generally candidates for chemoprevention and can be evaluated and counseled in a high-risk breast clinic. Knowledge about drugs that can prevent breast cancer may increase uptake among high-risk women. Methods: In a single practice, women with a diagnosis of atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), or severe atypical ductal hyperplasia/borderline ductal carcinoma in situ are offered an extended visit with a nurse practitioner in the Breast and Ovarian Cancer Risk and Prevention Clinic. The visit includes data collection, patient interview about relevant history and personal preferences, risk assessment, including use of relevant models (via HughesRiskApps.com), and recommendations for surveillance and prevention. Emphasis is placed on understanding of individual risk as well as risks and benefits and appropriateness of chemoprevention and surveillance modalities. Based on personal and family history, women are advised if chemoprevention is appropriate to consider, their choice is made, and they are encouraged to have surveillance in the Breast Clinic. Results: Since January 2001, 487 women with a diagnosis of ADH, ALH or LCIS, or severe ADH have been evaluated and counseled in the Breast and Ovarian Cancer Risk and Prevention Clinic. 132/487 (27%) were advised against taking chemoprevention and 355/487 (73%) were appropriate for chemoprevention. Of those for whom chemoprevention was clinically appropriate, 188/355 (53%) took one of the medications, or participated in a chemoprevention trial. 53/188 (28%) did not complete therapy (discontinued at 2 weeks to 54 months) due to preference or side effects. 75 women have completed five years of therapy and 60 are currently on therapy. Conclusions: When provided with personalized information about breast cancer risk and the pros and cons of chemoprevention, many women will choose to take medication to reduce breast cancer risk.

scholarly journals Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer

2005 ◽  
Vol 23 (28) ◽  
pp. 6890-6898 ◽  
Author(s):  
Joanna B. Madalinska ◽  
Judith Hollenstein ◽  
Eveline Bleiker ◽  
Marc van Beurden ◽  
Heiddis B. Valdimarsdottir ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
High Risk ◽  
Cancer Risk ◽  
Sexual Functioning ◽  
Short Form ◽  
High Risk Women ◽  
Increased Risk ◽  
Endocrine Symptoms

Purpose Recommendations for women at high risk of ovarian cancer include periodic gynecologic screening (GS) and prophylactic bilateral salpingo-oophorectomy (PBSO). The aim of the current study was to determine the quality-of-life (QOL) effects of PBSO versus GS. Patients and Methods Questionnaire data were obtained from 846 high-risk women who had participated in this nationwide, cross-sectional, observational study. Forty-four percent of the women had undergone PBSO, and 56% had opted for GS. Topics addressed by the questionnaire included generic QOL, cancer-specific distress, endocrine symptoms, and sexual functioning. Results No statistically significant between-group differences were observed in generic QOL (Short Form-36), with women in both the PBSO and GS groups scoring similarly to the general population. Compared with GS, PBSO was associated with fewer breast and ovarian cancer worries (P < .001) and more favorable cancer risk perception (P < .05). However, the PBSO group reported significantly more endocrine symptoms (P < .001) and worse sexual functioning (P < .05) than the GS group. Eighty-six percent of women would choose PBSO again, and 63% would recommend it to a friend with familial risk of ovarian cancer. Conclusion PBSO had no measurable adverse impact on generic QOL of high-risk women. The favorable effects of PBSO in terms of reduced cancer worries and low perceived cancer risk need to be weighed against the increase in endocrine and sexual symptoms. Balanced information will help clinicians and high-risk women to make informed decisions about the optimal preventive health strategy.

Abstract 3498: Ovarian cancer risk factors multiply to create high risk in pre-menopausal women

2020 ◽  
Author(s):  
Minh Tung Phung ◽  
Bhramar Mukherjee ◽  
Alice W. Lee ◽  
Penelope M. Webb ◽  
Harvey A. Risch ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ovarian Cancer ◽  
High Risk ◽  
Cancer Risk ◽  
Ovarian Cancer Risk ◽  
Cancer Risk Factors ◽  
Menopausal Women

Ovarian Cancer Risk And Prevention

2002 ◽  
Author(s):  
Suzanne M. Miller ◽  
Carolyn Y. Fang ◽  
Karen Hurley
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Ovarian Cancer Risk

scholarly journals A prospective study of postmenopausal hormone use and ovarian cancer risk

2006 ◽  
Vol 96 (1) ◽  
pp. 151-156 ◽  
Author(s):  
K N Danforth ◽  
S S Tworoger ◽  
J L Hecht ◽  
B A Rosner ◽  
G A Colditz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Prospective Study ◽  
Ovarian Cancer Risk ◽  
Postmenopausal Hormone ◽  
Hormone Use ◽  
A Prospective Study

A model for estimating ovarian cancer risk: Application for preventive oophorectomy

2015 ◽  
Vol 139 (2) ◽  
pp. 242-247 ◽  
Author(s):  
Vasily Giannakeas ◽  
Victoria Sopik ◽  
Konstantin Shestopaloff ◽  
Javaid Iqbal ◽  
Barry Rosen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Ovarian Cancer Risk
Sign in / Sign up

Export Citation Format

Share Document